Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer

S. Charoenfuprasert, Y. Y. Yang, Y. C. Lee, K. C. Chao, P. Y. Chu, C. R. Lai, K. F. Hsu, K. C. Chang, Y. C. Chen, L. T. Chen, J. Y. Chang, S. J. Leu, N. Y. Shih

研究成果: 雜誌貢獻文章

14 引文 (Scopus)

摘要

Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21 Waf/Cip1 and p27 Kip expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21 Waf/Cip1 expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.
原文英語
頁(從 - 到)3570-3584
頁數15
期刊Oncogene
30
發行號33
DOIs
出版狀態已發佈 - 八月 18 2011

指紋

Neoplasm Antigens
Ovarian Neoplasms
Carcinogenesis
Phosphotransferases
Salts
Adenomyosis
Peptide Library
Neoplasms
Cell Cycle Proteins
1-Phosphatidylinositol 4-Kinase
Ascitic Fluid
Leiomyoma
Humoral Immunity
Bacteriophages
Ovary
Cell Cycle
Cytoplasm
Cell Proliferation
Pharmacology

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

引用此文

Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. / Charoenfuprasert, S.; Yang, Y. Y.; Lee, Y. C.; Chao, K. C.; Chu, P. Y.; Lai, C. R.; Hsu, K. F.; Chang, K. C.; Chen, Y. C.; Chen, L. T.; Chang, J. Y.; Leu, S. J.; Shih, N. Y.

於: Oncogene, 卷 30, 編號 33, 18.08.2011, p. 3570-3584.

研究成果: 雜誌貢獻文章

Charoenfuprasert, S, Yang, YY, Lee, YC, Chao, KC, Chu, PY, Lai, CR, Hsu, KF, Chang, KC, Chen, YC, Chen, LT, Chang, JY, Leu, SJ & Shih, NY 2011, 'Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer', Oncogene, 卷 30, 編號 33, 頁 3570-3584. https://doi.org/10.1038/onc.2011.77
Charoenfuprasert, S. ; Yang, Y. Y. ; Lee, Y. C. ; Chao, K. C. ; Chu, P. Y. ; Lai, C. R. ; Hsu, K. F. ; Chang, K. C. ; Chen, Y. C. ; Chen, L. T. ; Chang, J. Y. ; Leu, S. J. ; Shih, N. Y. / Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. 於: Oncogene. 2011 ; 卷 30, 編號 33. 頁 3570-3584.
@article{8d63dff499354b11acc29fb20943d568,
title = "Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer",
abstract = "Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21 Waf/Cip1 and p27 Kip expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55{\%} of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97{\%}) to CA125 (65{\%}) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21 Waf/Cip1 expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85{\%} of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.",
keywords = "CA125, malignant ascitic fluid, ovarian cancer, phage display, tumor-associated antigen",
author = "S. Charoenfuprasert and Yang, {Y. Y.} and Lee, {Y. C.} and Chao, {K. C.} and Chu, {P. Y.} and Lai, {C. R.} and Hsu, {K. F.} and Chang, {K. C.} and Chen, {Y. C.} and Chen, {L. T.} and Chang, {J. Y.} and Leu, {S. J.} and Shih, {N. Y.}",
year = "2011",
month = "8",
day = "18",
doi = "10.1038/onc.2011.77",
language = "English",
volume = "30",
pages = "3570--3584",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "33",

}

TY - JOUR

T1 - Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer

AU - Charoenfuprasert, S.

AU - Yang, Y. Y.

AU - Lee, Y. C.

AU - Chao, K. C.

AU - Chu, P. Y.

AU - Lai, C. R.

AU - Hsu, K. F.

AU - Chang, K. C.

AU - Chen, Y. C.

AU - Chen, L. T.

AU - Chang, J. Y.

AU - Leu, S. J.

AU - Shih, N. Y.

PY - 2011/8/18

Y1 - 2011/8/18

N2 - Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21 Waf/Cip1 and p27 Kip expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21 Waf/Cip1 expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.

AB - Existence of humoral immunity has been previously demonstrated in malignant ascitic fluids. However, only a limited number of immunogenic tumor-associated antigens (TAAs) were identified, and few of which are associated with ovarian cancer. Here, we identified salt-inducible kinase 3 (SIK3) as a TAA through screening of a random peptide library in the phage display system. Overexpression of SIK3 markedly promoted cell proliferation, attenuated p21 Waf/Cip1 and p27 Kip expressions in low-grade OVCAR3 cells, and permitted the cells to grow in mice. Decrease in SIK3 expression in high-grade SK-OV3 cells consistently demonstrated its tumorigenic potency by modulating the protein levels of cell cycle regulators. When the expressions of SIK3 and CA125 were compared in cancer tissues, immunohistochemical (IHC) studies indicated that cytoplasm-localized SIK3 was highly expressed in 55% of the ovarian cancer samples. In contrast, it was rarely detected in adenomyosis, leiomyoma and normal ovary tissues, showing its higher specificity (97%) to CA125 (65%) in ovarian cancer. Moreover, experiments using pharmacological inhibitors to block SIK3-induced p21 Waf/Cip1 expression revealed that activation of c-Src and phosphoinositide-3-kinase were critically required for its biological activity, suggesting that they are the downstream signaling mediators of SIK3. These data were further supported by IHC studies, showing coexpression of c-Src with SIK3 in 85% of the ovarian tumor samples stained positive for SIK3. Collectively, our findings indicate that SIK3 is a novel ovarian TAA. Overexpression of SIK3 promotes G1/S cell cycle progression, bestows survival advantages to cancer cells for growth and correlates the clinicopathological conditions of patients with ovarian cancer.

KW - CA125

KW - malignant ascitic fluid

KW - ovarian cancer

KW - phage display

KW - tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=80051787302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051787302&partnerID=8YFLogxK

U2 - 10.1038/onc.2011.77

DO - 10.1038/onc.2011.77

M3 - Article

VL - 30

SP - 3570

EP - 3584

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 33

ER -